about
c-Myc regulates transcriptional pause releaseIntrinsically disordered proteins are potential drug targetsSmall-molecule inhibitors of the Myc oncoproteinc-Myc is a universal amplifier of expressed genes in lymphocytes and embryonic stem cellsThe impact of small molecule binding on the energy landscape of the intrinsically disordered protein C-mycLigand clouds around protein clouds: a scenario of ligand binding with intrinsically disordered proteinsHigh-Fidelity Reprogrammed Human IPSCs Have a High Efficacy of DNA Repair and Resemble hESCs in Their MYC Transcriptional SignatureDirect inhibition of c-Myc-Max heterodimers by celastrol and celastrol-inspired triterpenoids.Understanding protein non-folding.Division of labour between Myc and G1 cyclins in cell cycle commitment and pace controlEfficacy, pharmacokinetics, tisssue distribution, and metabolism of the Myc-Max disruptor, 10058-F4 [Z,E]-5-[4-ethylbenzylidine]-2-thioxothiazolidin-4-one, in mice.Small molecule inhibitors of Myc/Max dimerization and Myc-induced cell transformation.Pim1 promotes human prostate cancer cell tumorigenicity and c-MYC transcriptional activity.Role of MYC in B Cell Lymphomagenesis.c-MYC-Making Liver Sick: Role of c-MYC in Hepatic Cell Function, Homeostasis and Disease.Targeting protein-protein interactions for therapeutic intervention: a challenge for the future.c-Myc is required for the CHREBP-dependent activation of glucose-responsive genes.Pathological unfoldomics of uncontrolled chaos: intrinsically disordered proteins and human diseasesThe Myc 3' Wnt responsive element regulates neutrophil recruitment after acute colonic injury in mice.Evaluation of the antitumor effects of c-Myc-Max heterodimerization inhibitor 100258-F4 in ovarian cancer cells.In vitro cytotoxicity and in vivo efficacy, pharmacokinetics, and metabolism of 10074-G5, a novel small-molecule inhibitor of c-Myc/Max dimerization.Therapeutic Targeting of Myc.Targeting c-Myc as a novel approach for hepatocellular carcinoma.Mechanisms of small-molecule binding to intrinsically disordered proteins.MYC-dependent regulation and prognostic role of CIP2A in gastric cancer.Reverse engineering the neuroblastoma regulatory network uncovers MAX as one of the master regulators of tumor progression.Deregulated Myc requires MondoA/Mlx for metabolic reprogramming and tumorigenesisTargeting of the MYCN protein with small molecule c-MYC inhibitorscMyc is a principal upstream driver of beta-cell proliferation in rat insulinoma cell lines and is an effective mediator of human beta-cell replication.Small molecules targeting c-Myc oncogene: promising anti-cancer therapeuticsThe metabolic regulator ERRα, a downstream target of HER2/IGF-1R, as a therapeutic target in breast cancer.Identification of a novel E-box binding pyrrole-imidazole polyamide inhibiting MYC-driven cell proliferation.Perturbation of the c-Myc-Max protein-protein interaction via synthetic α-helix mimetics.Reversible linkage of two distinct small molecule inhibitors of Myc generates a dimeric inhibitor with improved potency that is active in myc over-expressing cancer cell lines.A complex task? Direct modulation of transcription factors with small molecules.Molecular classification, pathway addiction, and therapeutic targeting in diffuse large B cell lymphomaSmall Molecule Microarrays Enable the Identification of a Selective, Quadruplex-Binding Inhibitor of MYC Expression.Myc proteins in brain tumor development and maintenance.Cellular senescence and cancer chemotherapy resistance.Targeting intrinsically disordered proteins in neurodegenerative and protein dysfunction diseases: another illustration of the D(2) concept.
P2860
Q24629119-A02245C6-63A5-4A82-93FA-76E93AEC7D0EQ24633854-18E630BD-B828-483E-A0DC-A417A512D89DQ27025648-3EC03B71-C47F-4F74-BC14-55C35F813C4CQ28275988-73047317-1BEC-4CE4-80DD-B392F709B088Q28481319-02267995-4247-4F44-8E77-1F7B7E6DF5D1Q28534062-AC8455B7-2008-4BB9-98A9-3D1B98FDB3C5Q28595764-AC74AF47-9261-47AD-BA62-7C0A09E3F304Q30278518-360B21A0-9D0E-473C-946F-A25B7F932E79Q30385084-A641026B-E477-4A81-887D-61C255C7E9FAQ30587011-86EA2CF1-50E8-4D42-A423-5409DC552CD8Q33338530-32A990AA-21B2-43E1-B013-8A28A67CE4C5Q33508324-52D224CC-1C1F-4C58-B57E-4BD969ACD42DQ33591747-6D56DA35-1240-478F-B7BF-427696A0F5CEQ33608499-B12A06EB-FCF4-4DC4-9167-8B33738B076AQ33608524-D2A6B759-CCCA-4E2F-8A14-7DA9C1C8869CQ33852396-78DB264A-20A4-4E4B-948C-5D08A2B1E3BAQ33874328-35491907-2DA7-4123-9332-D7B5EB0CDDF2Q33909288-CF10FF05-642F-4E51-B69F-6BC7D0096806Q33923735-1480807B-E6B4-41ED-9FA4-D2E0D7A00BCDQ34161727-D79AEB09-C3BC-4FF1-A6DC-FDC823CC137CQ34359903-FDB5FDCB-FAE5-46C1-9C04-1C1FE050EFE4Q34373258-FABC26EA-D8BF-433E-BC03-CF29CBB27568Q34391522-5D0ADA60-B9E4-41E3-B619-B390E63267EDQ34417638-18F40B0F-C34A-487B-873D-DD79C4DDFEF0Q34983172-D35508EE-3A0F-44E3-B6F9-FE7CC14AB811Q35070297-A8DEA10D-7300-4BFF-AB3B-49DD1FEE5F8AQ35079601-4A9CAFE4-8225-47E8-904F-311AD30FDB75Q35173570-2876749B-FDA4-45D5-9979-E22D5617B044Q35238414-6C61B0D8-928A-49E2-BF75-F4EF7D57994DQ35353405-42078847-E234-4E30-8503-5EB4F92E238DQ35421284-5885CCDD-65DA-42DA-8D1E-AAE721807C6BQ35528327-DC7182BC-9440-47A2-AF39-2047EB580D3BQ35570730-9D0F2B76-CCCA-4F79-BFB9-6A71E3F8FDB2Q35601876-4B702D00-7518-4C96-BD30-26960B52A140Q35642431-AC259A7E-C7EB-4342-8523-05DD6834729EQ35797583-C951ADA0-80B3-4DAF-BF68-4252305F5CFEQ35805318-9C28D6AE-8D1A-4ED1-A85F-85D8F0D0127AQ35920494-1D5C0336-57B7-4FEB-9DD6-88E1E863DBBDQ35947022-7F3D295D-0EF5-447F-AF94-15459E5B51D3Q36020398-2ABE3324-A693-4E30-AE8D-AEE0A6EFD0F9
P2860
description
2007 nî lūn-bûn
@nan
2007 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Improved low molecular weight Myc-Max inhibitors.
@ast
Improved low molecular weight Myc-Max inhibitors.
@en
Improved low molecular weight Myc-Max inhibitors.
@nl
type
label
Improved low molecular weight Myc-Max inhibitors.
@ast
Improved low molecular weight Myc-Max inhibitors.
@en
Improved low molecular weight Myc-Max inhibitors.
@nl
prefLabel
Improved low molecular weight Myc-Max inhibitors.
@ast
Improved low molecular weight Myc-Max inhibitors.
@en
Improved low molecular weight Myc-Max inhibitors.
@nl
P2093
P1476
Improved low molecular weight Myc-Max inhibitors.
@en
P2093
Ariele Viacava Follis
Brian E Reese
Dalia I Hammoudeh
Edward V Prochownik
Huabo Wang
Steven J Metallo
P304
P356
10.1158/1535-7163.MCT-07-0005
P50
P577
2007-09-01T00:00:00Z